Erschienen in:
01.06.2007 | Commentary
Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
verfasst von:
Vladislava Simkova, Peter Radermacher, Eberhard Barth
Erschienen in:
Critical Care
|
Ausgabe 3/2007
Einloggen, um Zugang zu erhalten
Abstract
Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines).